These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22903479)

  • 1. Association of serum YKL-40 level with tumor burden and metastatic stage of prostate cancer.
    Özdemir E; Çiçek T; Kaya MO
    Urol J; 2012; 9(3):568-73. PubMed ID: 22903479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia.
    Kucur M; Isman FK; Balci C; Onal B; Hacibekiroglu M; Ozkan F; Ozkan A
    Urol Oncol; 2008; 26(1):47-52. PubMed ID: 18190830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.
    Thöm I; Andritzky B; Schuch G; Burkholder I; Edler L; Johansen JS; Bokemeyer C; Schumacher U; Laack E
    Cancer; 2010 Sep; 116(17):4114-21. PubMed ID: 20564116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
    Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
    Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
    Zhang YX; Wang L; Ji PY; Zhao GG; Zhong GP; Wang ZP
    Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early detection and prognosis of ovarian cancer using serum YKL-40.
    Dupont J; Tanwar MK; Thaler HT; Fleisher M; Kauff N; Hensley ML; Sabbatini P; Anderson S; Aghajanian C; Holland EC; Spriggs DR
    J Clin Oncol; 2004 Aug; 22(16):3330-9. PubMed ID: 15310777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
    Diefenbach CS; Shah Z; Iasonos A; Barakat RR; Levine DA; Aghajanian C; Sabbatini P; Hensley ML; Konner J; Tew W; Spriggs D; Fleisher M; Thaler H; Dupont J
    Gynecol Oncol; 2007 Feb; 104(2):435-42. PubMed ID: 17023034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival.
    Johansen JS; Brasso K; Iversen P; Teisner B; Garnero P; Price PA; Christensen IJ
    Clin Cancer Res; 2007 Jun; 13(11):3244-9. PubMed ID: 17545529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnostic and prognostic value of serum YKL-40 in endometrial cancer.
    Fan JT; Si XH; Liao Y; Shen P
    Arch Gynecol Obstet; 2013 Jan; 287(1):111-5. PubMed ID: 22945838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma.
    Brasso K; Christensen IJ; Johansen JS; Teisner B; Garnero P; Price PA; Iversen P
    Prostate; 2006 Apr; 66(5):503-13. PubMed ID: 16372331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum YKL-40 in risk assessment for colorectal cancer: a prospective study of 4,496 subjects at risk of colorectal cancer.
    Johansen JS; Christensen IJ; Jørgensen LN; Olsen J; Rahr HB; Nielsen KT; Laurberg S; Brünner N; Nielsen HJ
    Cancer Epidemiol Biomarkers Prev; 2015 Mar; 24(3):621-6. PubMed ID: 25597749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YKL-40 protein correlates with the phenotype of asthma.
    Specjalski K; Chełmińska M; Jassem E
    Lung; 2015 Apr; 193(2):189-94. PubMed ID: 25663327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial cancer.
    Kemik P; Saatli B; Yıldırım N; Kemik VD; Deveci B; Terek MC; Koçtürk S; Koyuncuoğlu M; Saygılı U
    Gynecol Oncol; 2016 Jan; 140(1):64-9. PubMed ID: 26607777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated serum YKL-40 level predicts poor prognosis in hepatocellular carcinoma after surgery.
    Zhu CB; Chen LL; Tian JJ; Su L; Wang C; Gai ZT; Du WJ; Ma GL
    Ann Surg Oncol; 2012 Mar; 19(3):817-25. PubMed ID: 21861215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
    Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
    Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.
    Spencer JA; Chng WJ; Hudson E; Boon AP; Whelan P
    Br J Radiol; 1998 Nov; 71(851):1130-5. PubMed ID: 10434906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment Serum Cystatin C Levels Predict Renal Function, but Not Tumor Characteristics, in Patients with Prostate Neoplasia.
    Yang F; Li D; Di Y; Zhang Y; Zang Y; Ren J; Yan L; Zhou Z; Liu H; Xu Z
    Biomed Res Int; 2017; 2017():7450459. PubMed ID: 28812020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with colorectal cancer.
    Liu X; Zhang Y; Zhu Z; Ha M; Wang Y
    Med Oncol; 2014 Aug; 31(8):85. PubMed ID: 24996799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.
    Schmidt H; Johansen JS; Sjoegren P; Christensen IJ; Sorensen BS; Fode K; Larsen J; von der Maase H
    J Clin Oncol; 2006 Feb; 24(5):798-804. PubMed ID: 16391295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.